Alligator Bioscience is currently conducting a rights issue aimed at advancing mitazalimab towards phase III and securing a partnership. CEO joins BioStock’s studio to discuss the recently announced cost-saving program, mitazalimab’s clinical data, and the company’s efforts to achieve a partnership for the candidate.
– A number of companies are doing due diligence, says Søren Bregenholt.
Watch the interview below:
This material has been prepared for marketing purposes and is not, and should not be considered, a prospectus according to applicable laws and regulations. The complete terms of the rights issue and more information about the company have been presented in a prospectus that has been disclosed and published on the aforementioned company’s website.
